ArticleCureus2026
When Tapering Is Not an Option: Transitioning From High-Dose Methadone to Buprenorphine.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methadone is a commonly used medication for opioid use disorder (OUD) but carries known risks, including corrected QT interval (QTc) prolongation and ventricular arrhythmias. Current guidelines recommend gradual methadone tapering or buprenorphine microdosing when transitioning to buprenorphine to minimize precipitated withdrawal. However, evidence guiding management when methadone must be urgently discontinued because of medical contraindications is limited. We describe a 41-year-old woman with OUD receiving high-dose methadone who presented after cardiac arrest with marked QTc prolongation, hypokalemia, and suspected methadone-associated cardiotoxicity. Given the life-threatening risk of ventricular arrhythmias, methadone was discontinued without tapering. The patient was managed symptomatically with short-acting opioids for withdrawal and was subsequently initiated on buprenorphine approximately 60 hours after her last methadone dose, once moderate withdrawal had developed. Although she experienced transient worsening of withdrawal symptoms after induction, she stabilized within 48 hours and was discharged on maintenance buprenorphine with outpatient follow-up. While gradual tapering remains standard practice, this case demonstrates that complete methadone cessation without tapering, followed by appropriately timed buprenorphine initiation, may be feasible when rapid discontinuation is medically necessary. Careful monitoring, shared decision-making, and symptomatic support remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.